The United Laboratories International Holdings (HK:3933) has released an update.
The United Laboratories International Holdings Limited has successfully enrolled the first subject in their Phase IIa clinical trial in China for TUL12101 Eye Drops, aiming to treat dry eye syndrome. This follows positive Phase I trial results, indicating good safety and tolerability of the drops. The company, a pioneer in developing RASP inhibitors in China, is looking to strengthen its position in the ophthalmic drug market.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.